CN114369555A - Alcaligenes faecalis T16 and application thereof - Google Patents
Alcaligenes faecalis T16 and application thereof Download PDFInfo
- Publication number
- CN114369555A CN114369555A CN202210098108.3A CN202210098108A CN114369555A CN 114369555 A CN114369555 A CN 114369555A CN 202210098108 A CN202210098108 A CN 202210098108A CN 114369555 A CN114369555 A CN 114369555A
- Authority
- CN
- China
- Prior art keywords
- lca
- alcaligenes faecalis
- udca
- conversion
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000588813 Alcaligenes faecalis Species 0.000 title claims abstract description 33
- 229940005347 alcaligenes faecalis Drugs 0.000 title claims abstract description 33
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims abstract description 26
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims abstract description 25
- 238000004321 preservation Methods 0.000 claims abstract description 3
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 44
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 44
- 229960001661 ursodiol Drugs 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000002028 Biomass Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 230000009466 transformation Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 241000588986 Alcaligenes Species 0.000 description 4
- 241000272525 Anas platyrhynchos Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 241001052560 Thallis Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 2
- 235000019838 diammonium phosphate Nutrition 0.000 description 2
- 229910052564 epsomite Inorganic materials 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- XBSQTYHEGZTYJE-OETIFKLTSA-N glycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 XBSQTYHEGZTYJE-OETIFKLTSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QBYUNVOYXHFVKC-GBURMNQMSA-N taurolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 QBYUNVOYXHFVKC-GBURMNQMSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057969 Reflux gastritis Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052927 chalcanthite Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009654 indole test Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052603 melanterite Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/06—Hydroxylating
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses an alcaligenes faecalis T16 and application thereof. The strain is named Alcaligenes faecalis T16, is deposited in China center for type culture Collection at 11/17/2021, and has a preservation number of CCTCC NO: m20211431. The invention discovers an Alcaligenes faecalis T16 which can convert LCA into UDCA, has certain tolerance to high-concentration LCA and can meet the requirement of industrial application.
Description
Technical Field
The invention belongs to the field of ursodeoxycholic acid synthesis, and particularly relates to an alcaligenes faecalis T16 and application thereof.
Background
Lithocholic acid (LCA) is not directly biosynthesized from cholesterol in the liver, but is a substance produced by chenodeoxycholic acid through bacterial metabolism in the intestine, which is a secondary bile acid present in bile of higher vertebrates. This substance produced in the intestine is mostly excreted together with the feces, and a very small part is absorbed, and a binding reaction occurs in the liver, and it appears in bile in the form of taurolithocholic acid (taurolithocholic acid) or glycolithocholic acid (glycolithocholic acid). LCA is widely present in bile of animals such as pig, cattle and sheep, and can be extracted and separated from the bile of the animals, however, in ton of slaughter wastes, many bile acids such as LCA are still unavailable and are finally discarded. In addition, LCA is a less toxic important secondary bile acid, and its accumulation is a major factor in liver damage during cholestasis, and also a risk factor for colon cancer and inflammation. LCA has stronger toxicity than other bile acids, and a large amount of feed to experimental animals can cause various kinds of trouble of liver and biliary tract systems.
Ursodeoxycholic acid (UDCA) is an effective component of traditional Chinese medicines, is also a medicine approved by the U.S. Food and Drug Administration (FDA) as only one first-line clinical medicine for treating Primary Biliary Cirrhosis (PBC), has very wide clinical application and excellent medicinal value, and can regulate metabolism in the liver. Research results show that the biological functions of ursodeoxycholic acid in vivo mainly include the following aspects: capable of increasing low density lipoprotein binding; can stimulate proliferation of liver cells; can enhance the therapeutic effect of interferon on chronic viral hepatitis; can promote the receptor activation of glucocorticoid and inhibit the tumor initiation and the migration of tumor cells; has good curative effect in the aspects of treating gallstone, bile reflux gastritis, alcoholic liver, biliary cirrhosis, hepatitis induced by medicaments, promoting liver transplantation and the like, and has large market consumption. Ursodeoxycholic acid, originally mainly extracted from natural bear gall, but live bear resources are very limited and violate animal protection laws.
Therefore, it is very interesting to propose a new method for synthesizing UDCA from lithocholic acid.
Disclosure of Invention
The invention adopts LCA as a unique carbon source to screen an Alcaligenes faecalis T16 which is tolerant to LCA and can convert LCA into UDCA, wherein the Alcaligenes faecalis T16 is named as Alcaligenes faecalis T16, is preserved in China center for type culture collection at 11.17.2021, and has a preservation number of CCTCC NO: m20211431. The 16S rDNA gene sequence of the gene has the sequence shown in SEQ ID No: 1 is shown. When the concentration of LCA is 5g/L, the conversion rate is the highest and reaches 73.8%, and the strain can tolerate 10g/L of LCA and meets the requirement of industrial application.
The invention has the beneficial effects that: the invention discovers an Alcaligenes faecalis T16 which can convert LCA into UDCA, has certain tolerance to high-concentration LCA and can meet the requirement of industrial application.
Drawings
FIG. 1 shows a colony morphology of Alcaligenes faecalis T16.
Detailed Description
The concept and technical effects of the present invention will be clearly and completely described below in conjunction with the embodiments and the accompanying drawings to fully understand the objects, aspects and effects of the present invention.
Example 1:
first, screening and related experiments of Alcaligenes faecalis T16:
(1) screening a culture medium:
plate screening culture medium: CH (CH)3COONH3 5g/L、NaNO3 5g/L、LCA 1g/L、MgSO4·7H2O 0.5g/L、MnSO4·H2O 0.01g/L、Na2HPO4 25g/L、NaH2PO44.4g/L, Tween 801 mL/L and agar 20 g/L.
Transformation medium: CH (CH)3COONH3 5g/L、KCl2 2g/L、K2HPO4 2g/L、LCA 1g/L、MgSO4·7H2O 0.5g/L、CaCl2 0.5g/L、FeSO4·7H2O 0.01g/L、CuSO4·5H2O 0.01g/L、Na2MoO4·2H2O 0.01mg/L、FeSO4·7H2O0.01 mg/L and Tween 801 mL/L.
Fermentation medium: 10g/L of tryptone, 5g/L of yeast extract, 10g/L of sodium chloride, 801 mL/L of tween and 1g/L of LCA.
Carbon source optimization culture medium: different carbon sources are 5g/L, tryptone 10g/L, sodium chloride 10g/L, tween 801 mL/L and LCA 1 g/L. The different carbon sources include lactose, soluble starch, glucose, beef extract, citric acid, sucrose and glycerol.
Carbon source optimization culture medium: 5g/L of different nitrogen sources, 5g/L of optimal carbon source, 10g/L of sodium chloride, 801 mL/L of tween and 1g/L of LCA. The different nitrogen sources include beef extract, peptone, urea, ammonium sulfate, diammonium phosphate, ammonium oxalate and diammonium hydrogen citrate.
(2) The screening method comprises the following steps:
1. weighing 10g of duck pond sludge in the Ruzhou city Linchuan river east countryside home village, putting the duck pond sludge into a triangular flask filled with 90mL of sterile water, putting the triangular flask into a shaking table, oscillating at 150rpm for 60min, taking out the duck pond sludge, and gradually diluting the duck pond sludge into 10-1、10-2、10-3、10-4、10-5、10-6The 6 concentrations of the diluted solution are respectively coated on a flat plate for screening, and the diluted solution is statically cultured for 3-6d at 27 ℃. A single colony on a selected plate is inoculated into a transformation medium culture medium and cultured for 14d at the temperature of 27 ℃ and the rpm of 200.
TCL detection LCA: the method comprises the following steps of 1: 1 volume of ethyl acetate extraction, run TCL for preliminary characterization. The chromatography agent is dichloromethane: acetone: glacial acetic acid 20: 10: 1, color developing agent: 4.5% phosphomolybdic acid.
3. Amplification experiment: all possible strains were inoculated into a tube containing 5mL of fermentation medium at 27 ℃ for 2 days at 200rpm, and the cells were collected by centrifugation (50mL centrifuge tube) and washed with PBS.
Each centrifuge tube (with cells) was filled with 40mL of transformation medium, mixed well, and cultured at 27 ℃ for 14 days at 200 rpm.
Dividing 40mL of liquid into two parts, extracting with ethyl acetate with the same volume, drying, dissolving with chromatographic pure methanol, and detecting with liquid chromatography.
4. Liquid chromatography detection of UDCA: c18 column, methanol: phosphoric acid aqueous solution (pH 2) 80: 20, flow rate: 0.8mL/min, wavelength: 210nm, column temperature: 35 ℃ is carried out.
5. Optimizing fermentation conditions: different carbon sources, nitrogen sources, temperatures (15-40 ℃) and pH values (3-10) are optimized under different fermentation conditions, and the optimized results are detected by liquid chromatography.
6. Optimizing transformation conditions: optimizing transformation conditions in transformation media with different temperatures (20-60 ℃) and different pH values (3-10), and detecting the optimized result by liquid chromatography.
7. The effect of varying concentrations of LCA on the conversion of LCA by Alcaligenes faecalis T16 to UDCA.
Second, result in
(1) LCA is used as a unique carbon source to screen a bacterial strain Alcaligenes fa eclalis T16 capable of converting LCA to obtain UDCA, wherein the bacterial colony is circular and light yellow, the surface of the bacterial colony is smooth, wet and slightly glossy, the middle of the bacterial colony is convex, the bacterial colony is opaque, the edge of the bacterial colony is neat, the texture of the bacterial colony is thick, gram staining is negative, and the morphology of the bacterial colony is shown in figure 1.
The strain can not ferment saccharides, has positive reaction of oxidase and catalase, has negative reaction of indole test, M-R test, V-P test, gelatin liquefaction test and amylase test, can utilize nitrate and nitrite, meets the description of the Alcaligenes in Bergey's Manual of bacteria identification, and is preliminarily identified as Alcaligenes. Extracting T16 genome, wherein the 16S rDNA gene sequence of the T16 genome is SEQ ID No: 1, and the following components:
AGTATCCCCCGTGGTAGCGCCCTCCTTACGGTTAGGCTACCTACTTCTGGTGAAACCCACTCCCATGGTGTGACGGGCGGTGTGTACAAGACCCGGGAACGTATTCACCGCGACATTCTGATCCGCGATTACTAGCGATTCCGACTTCACGCAGTCGAGTTGCAGACTGCGATCCGGACTACGATCGGGTTTCTGAGATTGGCTCCCCCTCGCGGGTTGGCGACCCTCTGTCCCGACCATTGTATGACGTGTGAAGCCCTACCCATAAGGGCCATGAGGACTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCTCATTAGAGTGCTCTTGCGTAGCAACTAATGACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCAGCACCTGTGTTCCcGGTTCTCtTGCGAGCACGGCCAAATCTCTTCGGCTTTCCAGACATGTCAAGGGTAGGTAAGGTTTTtCGCGTTGCATCGAATTAATcCACATCATCCACCGCTTGTGCGGGTCCCCGTCAATTCCTTTGAGTTTTAATCTTGCGACCGTACTCCCCAGGCGGTCAACTTCACGCGTTAGCTGCGCTACTAAGGCCTAACGGCCCCAACAGCTAGTTGACATCGTTTAGGGCGTGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGTGTCTGAGCGTCAGTATTATCCCAGGGGGCTGCCTTCGCCATCGGTATTCCTCCACATATCTACGCATTTCACTGCTACACGTGGAATTCTACCCCCCTCTGACATACTCTAGCTCGGCAGTTAAAAATGCAGTTCCAAGGTTGAGCCCTGGGATTTCACATCTTTCTTTCCGAACCGCCTACACACGCTTTACGCCCAGTAATTCCGATTAACGCTTGCACCCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGTGCTTATtCTGCAGATACCGTCAGCAGTACCTCGTATTAGGAGGTACCTTTTCTTCTCTGCCAAAaGTACTTTACAACCCGAAGGCcTTCATCATACACGCGGGATGGCTGGATCAGGGTTTCCCCCATTGTCCAAAATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCTGGTCGTCCTCTCAAACCAGCTACGGATCGTTGCCTTGGTGAGCCTTTACCCCACCAACTAGCTAATCCGATATCGGCCGCTCCAATAGTGAGAGGTCTTGCGATCCCCCCCTTTCCCCCGTAGGGCGTATGCGGTATTAGCCACTCTTTCGAGTAGTTATCCCCCGCTACTGGGCACGTTCCGATATATTACTCACCCGTCCGCCACTCGCCGCCAAGAGAGCAAGCTCTCTCGCGCTGCCGTTCGACTGCATGTTAAAGCTGCCCAAGG。
the universal forward primer BSF8(5 '-agaggtttgatcctggcctcag-3') and the universal reverse primer BSR1492(5 '-ggctact tagagactt-3') were PCR amplified, and the BLAST result at NCBI after sequencing was Alcaligenes faecalis, so the name is: alcaligenes faecalis T16.
(2) The effect of different carbon sources on the biomass of Alcaligenes faecalis T16 and the conversion of LCA to UDCA:
the fermentation medium takes peptone 10g/L as a nitrogen source, and the following carbon sources of lactose, starch, glucose, beef extract, citric acid, sucrose and glycerol are respectively added according to the concentration of 5 g/L. The results are shown in Table 1. As can be seen from table 1: the carbon source has obvious influence on the biomass of the thalli and has larger influence on the conversion rate, when glucose and sucrose are used as the carbon source, the thalli grow vigorously, the biomass is higher, the conversion rates respectively reach 73.1 percent and 73.8 percent, and the optimal carbon source is sucrose.
TABLE 1
(3) The effect of different nitrogen sources on the biomass of Alcaligenes faecalis T16 and the conversion of LCA to UDCA:
the enzyme production medium takes 5g/L glucose as a carbon source, and the following nitrogen sources are respectively added according to 10 g/L: beef extract, peptone, urea, ammonium sulfate, diammonium hydrogen phosphate, ammonium oxalate and diammonium hydrogen citrate. The cells cultured at 27 ℃ and 220rpm/min for 2 days were subjected to transformation experiments. The results are shown in Table 2. As can be seen from Table 2, the nitrogen source has a large influence on both biomass and conversion rate of the cells, wherein the cells grow vigorously when peptone and ammonium sulfate are used as carbon sources, the biomass is relatively high, the conversion rates reach 71.9% and 73.2%, respectively, and the optimal nitrogen source is peptone.
TABLE 2
(4) The effect of different culture temperatures on the biomass of Alcaligenes faecalis T16 and the conversion of LCA to UDCA:
temperature is an important factor influencing cell growth and enzyme production by fermentation, influences of different fermentation temperatures on the yield and the conversion rate of thalli of the Alcaligenes faecalalis T16 strain are examined, and as a result, the temperature has certain influences on the biomass and the conversion rate, when the culture temperature of thalli is 30 ℃, the biomass and the conversion rate are the highest, the conversion rate reaches 73.5%, so that 30 ℃ is taken as the optimal fermentation temperature, and the table 3 shows that the biomass and the conversion rate are optimal.
TABLE 3
(5) Effect of initial medium pH on Alcaligenes faecalis T16 biomass and conversion of LCA to UDCA:
the growth of the cells and the activity of various enzymes of the cells are regulated by the initial pH of the medium. To examine the effect of initial pH on biomass of Alcaligenes faecalis T16 and conversion of LCA to UDCA. The fermentation medium was adjusted to different pH values, and the cells obtained by the culture were subjected to LCA transformation to obtain UDCA. As a result, all the microbial cells grew in the medium at pH4.0 to 10.0, the biomass and the conversion rate were highest at pH7, and the conversion rate reached 73.8%, as shown in Table 4.
TABLE 4
(6) Influence of transformation temperature on the biomass of Alcaligenes faecalis T16 and the conversion of LCA to UDCA:
the results of the effect of the conversion temperature on the conversion of LCA to UDCA by Alcaligenes faecalis T16 are shown in Table 5, 30 ℃ being the optimum conversion temperature, and the conversion decreasing with increasing temperature above 30 ℃.
TABLE 5
(7) Effect of transformation medium pH on Alcaligenes faecalis T16 Biomass and transformation of LCA to UDCA:
the results of the effect of pH on the conversion of LCA to UDCA by Alcaligenes faecalis T16 are shown in Table 6. As can be seen from Table 6, the optimum pH of the transformation medium was 8, the catalytic effect was the best under slightly alkaline conditions, and too high or too low pH was detrimental to transformation.
TABLE 6
(8) The effect of different concentrations of LCA on the biomass of Alcaligenes faecalis T16 and the conversion of LCA to UDCA:
the results of the effect of varying concentrations of LCA on the conversion of LCA by Alcaligenes faecalis T16 to UDCA are shown in Table 7. As can be seen from Table 7, the highest conversion reached 73.8% at an LCA concentration of 5g/L, and the conversion decreased gradually with increasing LCA concentration when the LCA concentration exceeded 10g/L, but 10g/L of LCA was tolerated.
TABLE 7
The above description is only a preferred embodiment of the present invention, and the present invention is not limited to the above embodiment, and the present invention shall fall within the protection scope of the present invention as long as the technical effects of the present invention are achieved by the same means. The invention is capable of other modifications and variations in its technical solution and/or its implementation, within the scope of protection of the invention.
SEQUENCE LISTING
<110> institute of microbiology of academy of sciences of Jiangxi province
<120> Alcaligenes faecalis T16 and application thereof
<130> 2022
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 1436
<212> DNA
<213> Alcaligenes faecalis T16
<400> 1
agtatccccc gtggtagcgc cctccttacg gttaggctac ctacttctgg tgaaacccac 60
tcccatggtg tgacgggcgg tgtgtacaag acccgggaac gtattcaccg cgacattctg 120
atccgcgatt actagcgatt ccgacttcac gcagtcgagt tgcagactgc gatccggact 180
acgatcgggt ttctgagatt ggctccccct cgcgggttgg cgaccctctg tcccgaccat 240
tgtatgacgt gtgaagccct acccataagg gccatgagga cttgacgtca tccccacctt 300
cctccggttt gtcaccggca gtctcattag agtgctcttg cgtagcaact aatgacaagg 360
gttgcgctcg ttgcgggact taacccaaca tctcacgaca cgagctgacg acagccatgc 420
agcacctgtg ttcccggttc tcttgcgagc acggccaaat ctcttcggct ttccagacat 480
gtcaagggta ggtaaggttt ttcgcgttgc atcgaattaa tccacatcat ccaccgcttg 540
tgcgggtccc cgtcaattcc tttgagtttt aatcttgcga ccgtactccc caggcggtca 600
acttcacgcg ttagctgcgc tactaaggcc taacggcccc aacagctagt tgacatcgtt 660
tagggcgtgg actaccaggg tatctaatcc tgtttgctcc ccacgctttc gtgtctgagc 720
gtcagtatta tcccaggggg ctgccttcgc catcggtatt cctccacata tctacgcatt 780
tcactgctac acgtggaatt ctacccccct ctgacatact ctagctcggc agttaaaaat 840
gcagttccaa ggttgagccc tgggatttca catctttctt tccgaaccgc ctacacacgc 900
tttacgccca gtaattccga ttaacgcttg caccctacgt attaccgcgg ctgctggcac 960
gtagttagcc ggtgcttatt ctgcagatac cgtcagcagt acctcgtatt aggaggtacc 1020
ttttcttctc tgccaaaagt actttacaac ccgaaggcct tcatcataca cgcgggatgg 1080
ctggatcagg gtttccccca ttgtccaaaa ttccccactg ctgcctcccg taggagtctg 1140
ggccgtgtct cagtcccagt gtggctggtc gtcctctcaa accagctacg gatcgttgcc 1200
ttggtgagcc tttaccccac caactagcta atccgatatc ggccgctcca atagtgagag 1260
gtcttgcgat cccccccttt cccccgtagg gcgtatgcgg tattagccac tctttcgagt 1320
agttatcccc cgctactggg cacgttccga tatattactc acccgtccgc cactcgccgc 1380
caagagagca agctctctcg cgctgccgtt cgactgcatg ttaaagctgc ccaagg 1436
Claims (4)
1. An Alcaligenes faecalis T16, wherein the Alcaligenes faecalis T16 is named as Alcaligenes faecalis T16, and is preserved in China center for type culture Collection (CCTCC NO) at 11.17.2021, with the preservation number of CCTCC NO: m20211431.
2. The alcaligenes faecalis T16 according to claim 1, wherein the 16S rDNA gene sequence is SEQ ID No: 1 is shown.
3. Use of the alcaligenes faecalis T16 according to any of claims 1-2 for converting lithocholic acid to ursodeoxycholic acid.
4. Use according to claim 3, characterized in that the concentration of lithocholic acid is 5 g/L.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210098108.3A CN114369555B (en) | 2022-01-27 | 2022-01-27 | Alcaligenes faecalis T16 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210098108.3A CN114369555B (en) | 2022-01-27 | 2022-01-27 | Alcaligenes faecalis T16 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114369555A true CN114369555A (en) | 2022-04-19 |
CN114369555B CN114369555B (en) | 2024-02-09 |
Family
ID=81146227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210098108.3A Active CN114369555B (en) | 2022-01-27 | 2022-01-27 | Alcaligenes faecalis T16 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114369555B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110699297A (en) * | 2019-11-12 | 2020-01-17 | 中国石油集团川庆钻探工程有限公司 | Alcaligenes faecalis phenol subspecies and application thereof |
CN112852652A (en) * | 2021-01-15 | 2021-05-28 | 江南大学 | Recombinant yeast strain for efficiently converting chenodeoxycholic acid to synthesize ursodeoxycholic acid, construction and application |
-
2022
- 2022-01-27 CN CN202210098108.3A patent/CN114369555B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110699297A (en) * | 2019-11-12 | 2020-01-17 | 中国石油集团川庆钻探工程有限公司 | Alcaligenes faecalis phenol subspecies and application thereof |
CN112852652A (en) * | 2021-01-15 | 2021-05-28 | 江南大学 | Recombinant yeast strain for efficiently converting chenodeoxycholic acid to synthesize ursodeoxycholic acid, construction and application |
Non-Patent Citations (1)
Title |
---|
代同成等: "片烟产果胶酶细菌的鉴定及酶活测定", 微生物学通报, vol. 38, no. 6, pages 816 - 824 * |
Also Published As
Publication number | Publication date |
---|---|
CN114369555B (en) | 2024-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112262216B (en) | System for obtaining protein-rich nutritional supplements from bacterial fermentation processes | |
JP6913033B2 (en) | Gas fermentation for protein or feed production | |
CN106085881B (en) | A kind of Aspergillus niger strain and its application | |
WO2021237950A1 (en) | Process for manufacturing artificial bear bile powder | |
CN111004753B (en) | Lactobacillus paracasei capable of highly producing selenocysteine and application thereof | |
CN112280720B (en) | Bacteroides thetaiotaomicron GL-02 and complex microbial inoculum compounded with bile acid and application thereof | |
CN112760271B (en) | Process for producing clostridium butyricum through high-density fermentation under negative pressure condition and application | |
CN108641979A (en) | A kind of enterococcus faecium, its high density fermentation cultural method and probiotics prepared therefrom | |
CN108179122B (en) | High-adhesion probiotic enterococcus faecium and application thereof | |
CN111040973A (en) | Lactobacillus rhamnosus capable of highly producing 2 forms of organic selenium and application thereof | |
CN110089756A (en) | It is a kind of for promote enteron aisle generate short chain fatty acids and beneficial bacterium functional food additives | |
CN113151070B (en) | Lactobacillus fermentum capable of improving relative abundance of Guttiferae in intestinal tract | |
CN110934224B (en) | Yeast hydrolysate with high free nucleotide content and preparation method and application thereof | |
CN114369555A (en) | Alcaligenes faecalis T16 and application thereof | |
CN115968972A (en) | Composite selenium-rich microbial feed additive and application thereof | |
CN104273328A (en) | Cottonseed meal feed and preparation method thereof | |
CN113826778A (en) | Preparation method of composite probiotic for fermented feed | |
CN114395494B (en) | Saberlin Dener yeast T52 and application thereof | |
CN112852680A (en) | Liquid fermentation method of bacillus coagulans with high spore number | |
CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
CN117903953B (en) | Aspergillus oryzae for high yield of complex enzyme, fermentation liquor, preparation method and application thereof | |
CN108504589A (en) | A kind of compound lactobacillus probiotics and its preparation method and application | |
Tewari | Food and industrial microbiology | |
Kleine et al. | Whey disposal by deproteinization and fermentation | |
CN118185832A (en) | Method for improving tolerance of facultative anaerobic lactic acid bacteria in aerobic environment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |